

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts

WARREN, N.J., April 26, 2023 – [Tevogen Bio](#) is pleased to announce that its Chief Scientific Officer, Dr. Neal Flomenberg, will be presenting at the Long COVID, Inflammation, and Cancer Conclave, hosted by the No One Left Alone ([NOLA](#)) Foundation on May 12, 2023, in Charlotte, North Carolina. Dr. Flomenberg will be joining a distinguished group of global experts in oncology from various institutions, including the Broad Institute, COA, BCBSSC, Carolina Blood and Cancer Care Associates, Children's Hospital of Philadelphia, Johns Hopkins, Weill Cornell Medicine, Florida Cancer Specialists, UCSF, American Oncology Network, UCSD School of Medicine, and ASCO, to examine the links between Long COVID, cancer, cardiac conditions, and other long-term debilitating impacts on millions of Americans, with a focus on underserved and vulnerable populations.

Dr. Flomenberg's presentation will focus on Tevogen Bio's investigational T Cell Therapy for acute COVID-19, as well as Long COVID. "As the pandemic evolves, we've observed a shift in the challenges it presents. Our focus for acute COVID lies on vulnerable subpopulations. It is highly likely that Long COVID, and other late sequelae caused by the virus will garner increasing attention as the situation continues to evolve," remarked [Dr. Flomenberg](#).

"We are honored to have Dr. Flomenberg join our distinguished panel of experts at the conclave. His extensive knowledge of cytotoxic T lymphocyte therapy and expertise in cancer research, in alignment with Tevogen Bio's commitment to health equity, strongly support NOLA's mission to collaboratively address health disparities through research and education," stated [Dr. Kashyap Patel](#).

About Tevogen's Next Generation Precision T Cell Platform

Tevogen's next generation precision [T cell platform](#) is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple, precise candidate targets on viral or malignant cells are selected in advance for T cell sensitization and effector functions with the goal of overcoming the mutational escape capacity of cancer cells and viruses while limiting cross-reactivity.

Tevogen is investigating its technology's potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen's goal is to provide access to the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections. The ability to administer TVGN-489 in the outpatient setting and the ongoing work by Tevogen scientists to use this product in diverse patient populations, highlights Tevogen Bio's commitment to patient accessibility.

About Tevogen Bio

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible

personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.

Contacts

Tevogen Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com